Synopsys reported its Q4 results on September 30 and the stock closed down 0.6% to $415.09, a muted reaction that leaves the bullish setup from the past two weeks largely intact but still unconfirmed by price.
The options market has shifted decisively toward calls over the past week, and that shift has held through the print. The put/call ratio closed at 0.91 on Tuesday, well below its 20-day average of 1.08 and roughly 1.4 standard deviations on the bullish side of normal. That is a meaningful reversal from the defensive posture that dominated through August, when the PCR ran consistently above 1.15. Borrow conditions remain entirely unconstraining: availability is near 6,976%, meaning shares to borrow are effectively unlimited relative to existing short interest. Cost to borrow has risen about 35% over the past week to 0.48%, which sounds alarming in percentage terms but still leaves it in low-single-digit basis-point territory. Short interest has edged up 7.5% on the week to 3.1% of the free float, a modest position that is consistent with technical hedges rather than any directional short conviction.
The analyst community is one of the most uniformly bullish in the software sector right now. Eighteen analysts rate SNPS a Buy, four Outperform, and just two Hold. The consensus target of $553 implies roughly 33% upside from current levels. The most significant recent move came from HSBC, which upgraded to Buy on September 25 with a $700 target, one of the most aggressive on the Street. The bulls point to Q3 revenue of $2.48 billion, 42% year-over-year growth, management raising FY26 guidance, and the Ansys acquisition contributing synergies ahead of schedule. The bear case is narrower but real: backlog slipped sequentially to $10.9 billion from $11 billion in Q2, growth is concentrated in a few drivers, and the IP segment is not yet back to its historical growth rate. At a P/E of 24 and EV/EBITDA of 21, both of which have compressed over the past 30 days, valuation has moderated from the premium levels that constrained sentiment earlier in the year, though the EV/EBIT factor score still ranks in the bottom decile of the universe.
On ownership, T. Rowe Price added 567,200 shares as of September 1, making it the most active buyer among disclosed top holders. UBS Asset Management added 1.37 million shares through July. Capital World Investors, meanwhile, trimmed from 5.1% to 4.2% of shares in a November 2025 filing, dropping below the 5% reporting threshold. Per the standard disclosure caveat, 13D/G stakes are as-last-disclosed around that threshold, and Capital World's current position may differ without a further filing obligation.
The one signal worth watching after the print is how that options positioning evolves. The PCR has been running well below its 20-day mean for several sessions now, and the 52-week low sits at 0.43. If call demand stays elevated without a corresponding move in the stock, some of that positioning will decay. The next scheduled earnings event is December 2, 63 days out, which is the next natural catalyst for the Street's $553 consensus target to start closing the gap with the current $415 price.
See the live data behind this article on ORTEX.
Open SNPS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
